$PNW

TD Cowen Adjusts Price Target on Pinnacle West Capital to $106 From $101, Keeps Hold Rating

TD Cowen raised its price target for Pinnacle West Capital to $106 from $101 and maintained a Hold rating, according to the firm. The update matters for investors tracking utility-sector valuation and analyst expectations for the company’s shares.

Original reporting
Published Aug 12, 2026, 10:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PNW
Neutral
low confidence
Mentioned
$PNW
Relevance
4/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$PNWNeutralLow
01

Why it matters

For traders, the actionable signal is the target revision magnitude ($106 vs $101) but the lack of rating change suggests limited incremental information.

02

Market read

This is a modest valuation update for a single utility name, likely to have limited trading impact absent new fundamentals.

03

What to watch

Without any thesis details, traders should not infer changes to earnings power, regulatory outcomes, or capital plans from the target alone.

Relevance 4/10Novelty 4/10Timing: pre-market today (PT change published 08/12/2026)

Background

The piece is a sell-side update from TD Cowen adjusting its price target for Pinnacle West Capital while maintaining a Hold rating.

Company-level read

Ticker impact

$PNWNeutralLow confidence
Context

TD Cowen raised its price target on Pinnacle West Capital to $106 from $101 and kept a Hold rating, signaling a valuation update.

Expected impact

Likely limited near-term impact; any reaction should be muted versus a rating change or earnings/guidance update.

Evidence & confidence

The article provides only the new price target and unchanged Hold rating, with no additional fundamentals, catalysts, or new company disclosures.

Market effects

Minimal, since this is a single-name analyst target adjustment with no sector-wide catalyst described.

Minimal, no regional macro or utility sector event is cited.

Minimal, no cross-border transaction or global policy/regulatory development is mentioned.

Counterpoint

A higher price target with a Hold rating can reflect incremental optimism on valuation rather than improved fundamentals, so the market may discount it.

Key entities

  • Pinnacle West Capital

    Utility company covered by TD Cowen; subject of the price target adjustment.

  • TD Cowen

    Broker-dealer issuing the price target change and maintaining Hold rating.

Related articles

$PNWMedAI 8/10

Pinnacle West Capital (PNW) Q2 2026 Earnings Call Transcript

Pinnacle West Capital (PNW) reported Q2 2026 net income of $178.6M versus $192.6M in Q2 2025, with diluted EPS of $1.43 versus $1.58. Operating revenues rose to $1.46B from $1.36B. Management cited 9.6% weather-normalized sales growth, 9,164 MW peak demand, and a $265B Arizona TSMC investment plan. Full-year EPS guidance is $4.55 to $4.75.

$PNWMed

PINNACLE WEST REPORTS LOWER 2026 SECOND-QUARTER FINANCIAL RESULTS COMPARED TO A YEAR AGO

PINNACLE WEST CAPITAL CORP (PNW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 4, 2026 Media Contact: Analyst Contact: Alan Bunnell (602) 250-3376 Amanda Ho (602) 250-3334 Website: pinnaclewest.com PINNACLE WEST REPORTS LOWER 2026 SECOND-QUARTER FINANCIAL RESULTS COMPARED TO A YEAR AGO • Lower second-quarter financi

$MRNAHigh

Moderna's melanoma vaccine succeeds in major trial. So why did its stock plunge?

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

$VRTXMed

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.